JP2014532413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532413A5 JP2014532413A5 JP2014539033A JP2014539033A JP2014532413A5 JP 2014532413 A5 JP2014532413 A5 JP 2014532413A5 JP 2014539033 A JP2014539033 A JP 2014539033A JP 2014539033 A JP2014539033 A JP 2014539033A JP 2014532413 A5 JP2014532413 A5 JP 2014532413A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- segment
- animal
- endogenous
- segments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US61/552,582 | 2011-10-28 | ||
| US201261621198P | 2012-04-06 | 2012-04-06 | |
| US61/621,198 | 2012-04-06 | ||
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| US61/700,908 | 2012-09-14 | ||
| PCT/US2012/062065 WO2013063361A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified t cell receptor mice |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017205098A Division JP6532924B2 (ja) | 2011-10-28 | 2017-10-24 | 遺伝子改変ｔ細胞受容体マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532413A JP2014532413A (ja) | 2014-12-08 |
| JP2014532413A5 true JP2014532413A5 (enExample) | 2015-12-17 |
| JP6254528B2 JP6254528B2 (ja) | 2017-12-27 |
Family
ID=47178340
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539033A Active JP6254528B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変ｔ細胞受容体マウス |
| JP2017205098A Active JP6532924B2 (ja) | 2011-10-28 | 2017-10-24 | 遺伝子改変ｔ細胞受容体マウス |
| JP2018231026A Active JP6706311B2 (ja) | 2011-10-28 | 2018-12-10 | 遺伝子改変ｔ細胞受容体マウス |
| JP2020085787A Withdrawn JP2020146045A (ja) | 2011-10-28 | 2020-05-15 | 遺伝子改変ｔ細胞受容体マウス |
| JP2022075908A Active JP7305840B2 (ja) | 2011-10-28 | 2022-05-02 | 遺伝子改変ｔ細胞受容体マウス |
| JP2022208112A Active JP7656580B2 (ja) | 2011-10-28 | 2022-12-26 | 遺伝子改変ｔ細胞受容体マウス |
| JP2023214715A Withdrawn JP2024019646A (ja) | 2011-10-28 | 2023-12-20 | 遺伝子改変ｔ細胞受容体マウス |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017205098A Active JP6532924B2 (ja) | 2011-10-28 | 2017-10-24 | 遺伝子改変ｔ細胞受容体マウス |
| JP2018231026A Active JP6706311B2 (ja) | 2011-10-28 | 2018-12-10 | 遺伝子改変ｔ細胞受容体マウス |
| JP2020085787A Withdrawn JP2020146045A (ja) | 2011-10-28 | 2020-05-15 | 遺伝子改変ｔ細胞受容体マウス |
| JP2022075908A Active JP7305840B2 (ja) | 2011-10-28 | 2022-05-02 | 遺伝子改変ｔ細胞受容体マウス |
| JP2022208112A Active JP7656580B2 (ja) | 2011-10-28 | 2022-12-26 | 遺伝子改変ｔ細胞受容体マウス |
| JP2023214715A Withdrawn JP2024019646A (ja) | 2011-10-28 | 2023-12-20 | 遺伝子改変ｔ細胞受容体マウス |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9113616B2 (enExample) |
| EP (3) | EP3795587A1 (enExample) |
| JP (7) | JP6254528B2 (enExample) |
| KR (5) | KR101964776B1 (enExample) |
| CN (5) | CN114891797A (enExample) |
| AU (5) | AU2012327204B2 (enExample) |
| BR (1) | BR112014009203B1 (enExample) |
| CA (1) | CA2853707A1 (enExample) |
| CY (2) | CY1120945T1 (enExample) |
| DK (2) | DK3424947T3 (enExample) |
| ES (2) | ES2691475T3 (enExample) |
| HR (2) | HRP20181626T1 (enExample) |
| HU (1) | HUE053444T2 (enExample) |
| IL (4) | IL274914B2 (enExample) |
| IN (1) | IN2014CN03890A (enExample) |
| LT (2) | LT3424947T (enExample) |
| MX (2) | MX379517B (enExample) |
| PL (2) | PL2771357T3 (enExample) |
| PT (2) | PT2771357T (enExample) |
| RS (2) | RS57893B1 (enExample) |
| RU (1) | RU2661106C2 (enExample) |
| SG (2) | SG11201401030WA (enExample) |
| SI (2) | SI3424947T1 (enExample) |
| SM (2) | SMT202100243T1 (enExample) |
| WO (1) | WO2013063361A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114891797A (zh) * | 2011-10-28 | 2022-08-12 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| CN103212064B (zh) * | 2012-01-19 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| CN104364380B (zh) | 2012-04-25 | 2018-10-09 | 瑞泽恩制药公司 | 核酸酶介导的使用大靶向载体的靶向 |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA2908697C (en) | 2013-04-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| SG10201700961TA (en) | 2013-12-11 | 2017-04-27 | Regeneron Pharma | Methods and compositions for the targeted modification of a genome |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| HUE049776T2 (hu) * | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| HUE048677T2 (hu) * | 2014-06-19 | 2020-07-28 | Regeneron Pharma | Humanizált programozott sejthalál 1 génnel rendelkezõ nem-humán állatok |
| EP3161128B1 (en) | 2014-06-26 | 2018-09-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| WO2016044745A1 (en) * | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| EP3221457B1 (en) | 2014-11-21 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| KR20240055876A (ko) * | 2014-11-24 | 2024-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 cd3 복합체를 발현하는 비인간 동물 |
| JP6840077B2 (ja) | 2014-12-19 | 2021-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 |
| KR20240132525A (ko) * | 2015-04-06 | 2024-09-03 | 리제너론 파아마슈티컬스, 인크. | 비인간 동물에서의 인간화 t 세포 매개 면역반응 |
| PL3291679T3 (pl) | 2015-05-06 | 2022-04-25 | Snipr Technologies Limited | Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty |
| AU2016358101B2 (en) | 2015-11-20 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized Lymphocyte-activation gene 3 |
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| ES2914648T3 (es) | 2016-04-08 | 2022-06-15 | Immunocore Ltd | Receptores de células T |
| SI3462853T1 (sl) * | 2016-06-03 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EP3638262A4 (en) * | 2017-06-16 | 2021-03-24 | Mayo Foundation for Medical Education and Research | MATERIALS AND METHODS FOR INCREASING IMMUNE REACTION |
| CN111954679A (zh) | 2017-10-03 | 2020-11-17 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20210029707A (ko) * | 2018-04-05 | 2021-03-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물 |
| EP3845638A4 (en) * | 2018-07-26 | 2022-05-11 | Kyoto University | METHOD OF PRODUCTION OF A CELL DELIVERED BY A RECEPTOR GENE OF A FOREIGN ANTIGEN |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| CA3154287A1 (en) * | 2019-09-12 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2020395122A1 (en) | 2019-12-02 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Peptide-MHC II protein constructs and uses thereof |
| CN115485294A (zh) * | 2020-03-27 | 2022-12-16 | 2赛文缇生物公司 | T细胞受体 |
| CN113684258B (zh) | 2020-05-18 | 2024-08-20 | 上海赛比曼生物科技有限公司 | 用于检测鼠源tcr转基因拷贝数的试剂盒及方法 |
| AU2022249328A1 (en) | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| TW202417476A (zh) | 2022-08-18 | 2024-05-01 | 英商英美偌科有限公司 | Ｔ細胞受體及其融合蛋白 |
| KR20250077529A (ko) * | 2022-09-22 | 2025-05-30 | 리제너론 파아마슈티컬스, 인크. | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 |
| TW202520975A (zh) | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| GB2640828A (en) | 2024-04-22 | 2025-11-12 | T Therapeutics Ltd | Methods and products for the generation and identification of T cells and TCRs |
| GB2642411A (en) | 2024-04-22 | 2026-01-14 | T Therapeutics Ltd | T Cell Receptor identification and provision |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1994006908A1 (en) | 1992-09-11 | 1994-03-31 | The Regents Of The University Of California | Transgenic non-human animals having targeted lymphocyte transduction genes |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| US6320306B1 (en) * | 1996-08-05 | 2001-11-20 | Samsung Display Devices Co., Ltd. | Shadow mask with porous insulating layer and heavy metal layer |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7462486B2 (en) | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002222610A1 (en) * | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| AU2002246733B2 (en) * | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| EP1421115B1 (en) | 2001-08-31 | 2005-03-02 | Avidex Limited | Soluble t cell receptor |
| JP4087338B2 (ja) | 2001-11-15 | 2008-05-21 | キリンファーマ株式会社 | キメラ非ヒト動物 |
| DE60106469T2 (de) * | 2001-12-22 | 2005-10-13 | 4-Antbody AG | Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen |
| JP4238138B2 (ja) | 2001-12-22 | 2009-03-11 | ４−アンチボディ アーゲー | 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。 |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| AU2003279820A1 (en) * | 2002-10-30 | 2004-06-07 | The Wistar Institute Of Anatomy And Biology | Mouse model for autoimmune disorders |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| CA2651174A1 (en) * | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| WO2008051854A2 (en) | 2006-10-20 | 2008-05-02 | Trustees Of Boston University | A tunable genetic switch for regulating gene expression |
| JP2008159109A (ja) | 2006-12-21 | 2008-07-10 | Matsushita Electric Ind Co Ltd | データ転送装置 |
| WO2009114400A1 (en) | 2008-03-07 | 2009-09-17 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| WO2010107400A1 (en) * | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| CN102638971B (zh) * | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| US10765093B2 (en) | 2010-11-27 | 2020-09-08 | James Zhu | Humanized transgenic animal |
| CN114891797A (zh) * | 2011-10-28 | 2022-08-12 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| KR20240132525A (ko) | 2015-04-06 | 2024-09-03 | 리제너론 파아마슈티컬스, 인크. | 비인간 동물에서의 인간화 t 세포 매개 면역반응 |
-
2012
- 2012-10-26 CN CN202210507359.2A patent/CN114891797A/zh active Pending
- 2012-10-26 SI SI201231885T patent/SI3424947T1/sl unknown
- 2012-10-26 PL PL12784833T patent/PL2771357T3/pl unknown
- 2012-10-26 EP EP20198394.7A patent/EP3795587A1/en active Pending
- 2012-10-26 SG SG11201401030WA patent/SG11201401030WA/en unknown
- 2012-10-26 LT LTEP18176096.8T patent/LT3424947T/lt unknown
- 2012-10-26 KR KR1020147014477A patent/KR101964776B1/ko active Active
- 2012-10-26 EP EP18176096.8A patent/EP3424947B1/en active Active
- 2012-10-26 KR KR1020217035333A patent/KR102397961B1/ko active Active
- 2012-10-26 DK DK18176096.8T patent/DK3424947T3/da active
- 2012-10-26 EP EP12784833.1A patent/EP2771357B1/en active Active
- 2012-10-26 ES ES12784833T patent/ES2691475T3/es active Active
- 2012-10-26 LT LTEP12784833.1T patent/LT2771357T/lt unknown
- 2012-10-26 CN CN202210507387.4A patent/CN114891798B/zh active Active
- 2012-10-26 DK DK12784833.1T patent/DK2771357T3/en active
- 2012-10-26 MX MX2017012602A patent/MX379517B/es unknown
- 2012-10-26 SM SM20210243T patent/SMT202100243T1/it unknown
- 2012-10-26 SG SG10201914043XA patent/SG10201914043XA/en unknown
- 2012-10-26 IL IL274914A patent/IL274914B2/en unknown
- 2012-10-26 CN CN201710930556.4A patent/CN107858333B/zh active Active
- 2012-10-26 ES ES18176096T patent/ES2858978T3/es active Active
- 2012-10-26 PT PT12784833T patent/PT2771357T/pt unknown
- 2012-10-26 SI SI201231413T patent/SI2771357T1/sl unknown
- 2012-10-26 HU HUE18176096A patent/HUE053444T2/hu unknown
- 2012-10-26 JP JP2014539033A patent/JP6254528B2/ja active Active
- 2012-10-26 HR HRP20181626TT patent/HRP20181626T1/hr unknown
- 2012-10-26 CA CA2853707A patent/CA2853707A1/en active Pending
- 2012-10-26 CN CN201710930555.XA patent/CN107858332A/zh active Pending
- 2012-10-26 BR BR112014009203-6A patent/BR112014009203B1/pt active IP Right Grant
- 2012-10-26 MX MX2014004894A patent/MX353134B/es active IP Right Grant
- 2012-10-26 KR KR1020227015694A patent/KR102542272B1/ko active Active
- 2012-10-26 PT PT181760968T patent/PT3424947T/pt unknown
- 2012-10-26 CN CN201280064216.3A patent/CN104011071B/zh active Active
- 2012-10-26 US US13/661,342 patent/US9113616B2/en active Active
- 2012-10-26 KR KR1020197008815A patent/KR102148387B1/ko active Active
- 2012-10-26 WO PCT/US2012/062065 patent/WO2013063361A1/en not_active Ceased
- 2012-10-26 SM SM20180553T patent/SMT201800553T1/it unknown
- 2012-10-26 IL IL315445A patent/IL315445A/en unknown
- 2012-10-26 IN IN3890CHN2014 patent/IN2014CN03890A/en unknown
- 2012-10-26 PL PL18176096T patent/PL3424947T3/pl unknown
- 2012-10-26 RS RS20181207A patent/RS57893B1/sr unknown
- 2012-10-26 AU AU2012327204A patent/AU2012327204B2/en active Active
- 2012-10-26 IL IL305550A patent/IL305550B2/en unknown
- 2012-10-26 KR KR1020207024033A patent/KR102321909B1/ko active Active
- 2012-10-26 RS RS20210210A patent/RS61455B1/sr unknown
- 2012-10-26 RU RU2014121160A patent/RU2661106C2/ru active
-
2014
- 2014-04-13 IL IL232098A patent/IL232098B/en active IP Right Grant
-
2015
- 2015-07-14 US US14/799,355 patent/US11528895B2/en active Active
-
2016
- 2016-04-20 AU AU2016202512A patent/AU2016202512C1/en active Active
-
2017
- 2017-10-24 JP JP2017205098A patent/JP6532924B2/ja active Active
-
2018
- 2018-06-28 AU AU2018204700A patent/AU2018204700C1/en active Active
- 2018-10-16 CY CY181101057T patent/CY1120945T1/el unknown
- 2018-12-10 JP JP2018231026A patent/JP6706311B2/ja active Active
-
2020
- 2020-05-15 JP JP2020085787A patent/JP2020146045A/ja not_active Withdrawn
-
2021
- 2021-02-15 HR HRP20210256TT patent/HRP20210256T1/hr unknown
- 2021-02-19 CY CY20211100142T patent/CY1123831T1/el unknown
- 2021-05-18 AU AU2021203192A patent/AU2021203192B2/en active Active
-
2022
- 2022-05-02 JP JP2022075908A patent/JP7305840B2/ja active Active
- 2022-07-22 US US17/814,388 patent/US20220386575A1/en not_active Abandoned
- 2022-12-26 JP JP2022208112A patent/JP7656580B2/ja active Active
-
2023
- 2023-12-20 JP JP2023214715A patent/JP2024019646A/ja not_active Withdrawn
-
2024
- 2024-07-04 AU AU2024204645A patent/AU2024204645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532413A5 (enExample) | ||
| JP7386292B2 (ja) | 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物 | |
| RU2014121160A (ru) | Генетически модифицированные в отношении т-клеточного рецептора мыши | |
| AU2018206729C1 (en) | Animal models and therapeutic molecules | |
| US12356967B2 (en) | Immunoglobulin lambda light chain and uses thereof | |
| EP3609319B1 (en) | Mouse models and therapeutic molecules | |
| JP2017513520A5 (enExample) | ||
| CN108467873B (zh) | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 | |
| WO2011158009A1 (en) | Animal models and therapeutic molecules | |
| CN109136275A (zh) | 人源化gitr基因改造动物模型的制备方法及应用 | |
| TW202520975A (zh) | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 | |
| Eguren-Santamaria et al. | Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic | |
| KR20250116681A (ko) | 공통 경쇄를 발현하는 설치류 | |
| HK40058708B (en) | Rodent models and therapeutic molecules | |
| Wang | Molecular analysis of the interaction between T cell receptors and the VSV peptide presented by murine class I H-2K (b) molecules in TCR (alpha) chain transgenic mice | |
| HK40075382B (en) | Rodent models and therapeutic antibodies | |
| HK1180535B (en) | Animal models and therapeutic molecules |